These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21810032)

  • 1. Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.
    Mancuso C; Siciliano R; Barone E; Butterfield DA; Preziosi P
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1243-61. PubMed ID: 21810032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
    Farlow MR
    Mayo Clin Proc; 2006 Oct; 81(10):1350-8. PubMed ID: 17036561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs for Alzheimer's disease in Japan.
    Takeda M; Tanaka T; Okochi M
    Psychiatry Clin Neurosci; 2011 Aug; 65(5):399-404. PubMed ID: 21851448
    [No Abstract]   [Full Text] [Related]  

  • 6. [Mechanisms of action of Alzheimer medications].
    Alhainen K
    Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Newly approved drugs for Alzheimer disease: effectiveness and limitation].
    Yanagisawa K
    Brain Nerve; 2011 Aug; 63(8):863-8. PubMed ID: 21817177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Realistic expectations for treatment success in Alzheimer's disease.
    Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
    J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer disease and its management: a review.
    Samanta MK; Wilson B; Santhi K; Kumar KP; Suresh B
    Am J Ther; 2006; 13(6):516-26. PubMed ID: 17122533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil.
    Ota H; Ogawa S; Ouchi Y; Akishita M
    Exp Gerontol; 2015 Dec; 72():109-16. PubMed ID: 26408226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.
    Formiga F; Fort I; Robles MJ; Rodriguez D; Regalado P
    Dement Geriatr Cogn Disord; 2010; 29(3):198-203. PubMed ID: 20332637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuing Alzheimer's disease drug therapy: why, when, and how.
    Crutchfield D
    Director; 2008; 16(1):19-21. PubMed ID: 19343870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern care for patients with Alzheimer disease: rationale for early intervention.
    Galluzzi KE; Appelt DM; Balin BJ
    J Am Osteopath Assoc; 2010 Sep; 110(9 Suppl 8):S37-42. PubMed ID: 20926742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
    Schölzel-Dorenbos CJ;
    Tijdschr Gerontol Geriatr; 2005 Jul; 36(3):122-6. PubMed ID: 16078659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H; Grossberg GT
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
    Campanozzi MD; Casali E; Neviani F; Martini E; Neri M
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Alzheimer drugs: life-threatening adverse effects.
    Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17326275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New anti-AD drugs--their possibilities and issues].
    Nakamura Y
    Seishin Shinkeigaku Zasshi; 2012; 114(3):255-61. PubMed ID: 22568059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.